Brainsway (BWAY) Competitors

$16.32 +0.01 (+0.06%)

Closing price 04:00 PM Eastern

Extended Trading

$16.33 +0.01 (+0.06%)

As of 05:41 PM Eastern

BWAY vs. LMAT, WRBY, AXGN, ESTA, and NVCR

Should you buy Brainsway stock or one of its competitors? MarketBeat compares Brainsway with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Brainsway include LeMaitre Vascular (LMAT), Warby Parker (WRBY), AxoGen (AXGN), Establishment Labs (ESTA), and NovoCure (NVCR). These companies are all part of the "medical equipment" industry.

How does Brainsway compare to LeMaitre Vascular?

Brainsway (NASDAQ:BWAY) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

LeMaitre Vascular has higher revenue and earnings than Brainsway. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$52.23M	12.51	$7.57M	$0.35	46.63
LeMaitre Vascular	$249.60M	9.11	$57.73M	$2.71	36.72

LeMaitre Vascular has a net margin of 24.35% compared to Brainsway's net margin of 14.62%. LeMaitre Vascular's return on equity of 15.36% beat Brainsway's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	14.62%	11.10%	6.97%
LeMaitre Vascular	24.35%	15.36%	9.78%

30.1% of Brainsway shares are held by institutional investors. Comparatively, 84.6% of LeMaitre Vascular shares are held by institutional investors. 19.0% of Brainsway shares are held by company insiders. Comparatively, 7.4% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Brainsway currently has a consensus price target of $15.00, indicating a potential downside of 8.09%. LeMaitre Vascular has a consensus price target of $112.60, indicating a potential upside of 13.17%. Given LeMaitre Vascular's higher possible upside, analysts plainly believe LeMaitre Vascular is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Brainsway has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market. Comparatively, LeMaitre Vascular has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market.

In the previous week, LeMaitre Vascular had 4 more articles in the media than Brainsway. MarketBeat recorded 14 mentions for LeMaitre Vascular and 10 mentions for Brainsway. LeMaitre Vascular's average media sentiment score of 0.45 beat Brainsway's score of 0.41 indicating that LeMaitre Vascular is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainsway	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
LeMaitre Vascular	4 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

LeMaitre Vascular beats Brainsway on 12 of the 16 factors compared between the two stocks.

How does Brainsway compare to Warby Parker?

Brainsway (NASDAQ:BWAY) and Warby Parker (NYSE:WRBY) are both medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Brainsway has a net margin of 14.62% compared to Warby Parker's net margin of 0.15%. Brainsway's return on equity of 11.10% beat Warby Parker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	14.62%	11.10%	6.97%
Warby Parker	0.15%	2.30%	1.18%

Brainsway currently has a consensus price target of $15.00, indicating a potential downside of 8.09%. Warby Parker has a consensus price target of $29.00, indicating a potential upside of 0.38%. Given Warby Parker's higher possible upside, analysts plainly believe Warby Parker is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
Warby Parker	0 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.63

30.1% of Brainsway shares are held by institutional investors. Comparatively, 93.2% of Warby Parker shares are held by institutional investors. 19.0% of Brainsway shares are held by company insiders. Comparatively, 16.8% of Warby Parker shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Brainsway has higher earnings, but lower revenue than Warby Parker. Brainsway is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$52.23M	12.51	$7.57M	$0.35	46.63
Warby Parker	$871.91M	3.55	$1.64M	$0.02	1,444.55

In the previous week, Warby Parker had 8 more articles in the media than Brainsway. MarketBeat recorded 18 mentions for Warby Parker and 10 mentions for Brainsway. Warby Parker's average media sentiment score of 0.54 beat Brainsway's score of 0.41 indicating that Warby Parker is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainsway	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Warby Parker	7 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Brainsway has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market. Comparatively, Warby Parker has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market.

Summary

Brainsway and Warby Parker tied by winning 8 of the 16 factors compared between the two stocks.

How does Brainsway compare to AxoGen?

AxoGen (NASDAQ:AXGN) and Brainsway (NASDAQ:BWAY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Brainsway has a net margin of 14.62% compared to AxoGen's net margin of -13.21%. Brainsway's return on equity of 11.10% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
Brainsway	14.62%	11.10%	6.97%

AxoGen presently has a consensus price target of $46.50, indicating a potential upside of 13.55%. Brainsway has a consensus price target of $15.00, indicating a potential downside of 8.09%. Given AxoGen's higher possible upside, equities research analysts plainly believe AxoGen is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

80.3% of AxoGen shares are owned by institutional investors. Comparatively, 30.1% of Brainsway shares are owned by institutional investors. 2.4% of AxoGen shares are owned by insiders. Comparatively, 19.0% of Brainsway shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Brainsway has lower revenue, but higher earnings than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$238.11M	9.15	-$15.70M	-$0.64	N/A
Brainsway	$52.23M	12.51	$7.57M	$0.35	46.63

In the previous week, AxoGen had 4 more articles in the media than Brainsway. MarketBeat recorded 14 mentions for AxoGen and 10 mentions for Brainsway. AxoGen's average media sentiment score of 0.56 beat Brainsway's score of 0.41 indicating that AxoGen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AxoGen	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Brainsway	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

AxoGen has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

Summary

Brainsway beats AxoGen on 10 of the 16 factors compared between the two stocks.

How does Brainsway compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and Brainsway (NASDAQ:BWAY) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, profitability, earnings, media sentiment, dividends, analyst recommendations and institutional ownership.

Brainsway has a net margin of 14.62% compared to Establishment Labs' net margin of -19.05%. Brainsway's return on equity of 11.10% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
Brainsway	14.62%	11.10%	6.97%

Brainsway has lower revenue, but higher earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$229.58M	8.95	-$51.06M	-$1.49	N/A
Brainsway	$52.23M	12.51	$7.57M	$0.35	46.63

In the previous week, Brainsway had 2 more articles in the media than Establishment Labs. MarketBeat recorded 10 mentions for Brainsway and 8 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 0.71 beat Brainsway's score of 0.41 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Brainsway	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Establishment Labs has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.23, indicating that its stock price is 23% more volatile than the broader market.

Establishment Labs presently has a consensus price target of $87.14, indicating a potential upside of 24.85%. Brainsway has a consensus price target of $15.00, indicating a potential downside of 8.09%. Given Establishment Labs' higher probable upside, research analysts plainly believe Establishment Labs is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 30.1% of Brainsway shares are owned by institutional investors. 10.0% of Establishment Labs shares are owned by insiders. Comparatively, 19.0% of Brainsway shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Brainsway beats Establishment Labs on 11 of the 16 factors compared between the two stocks.

How does Brainsway compare to NovoCure?

Brainsway (NASDAQ:BWAY) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

Brainsway presently has a consensus price target of $15.00, suggesting a potential downside of 8.09%. NovoCure has a consensus price target of $27.29, suggesting a potential upside of 51.17%. Given NovoCure's higher probable upside, analysts plainly believe NovoCure is more favorable than Brainsway.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
NovoCure	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

30.1% of Brainsway shares are owned by institutional investors. Comparatively, 84.6% of NovoCure shares are owned by institutional investors. 19.0% of Brainsway shares are owned by company insiders. Comparatively, 5.5% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Brainsway has a net margin of 14.62% compared to NovoCure's net margin of -25.66%. Brainsway's return on equity of 11.10% beat NovoCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	14.62%	11.10%	6.97%
NovoCure	-25.66%	-50.82%	-16.48%

Brainsway has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market. Comparatively, NovoCure has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

Brainsway has higher earnings, but lower revenue than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$52.23M	12.51	$7.57M	$0.35	46.63
NovoCure	$674.41M	3.10	-$136.23M	-$1.53	N/A

In the previous week, Brainsway had 8 more articles in the media than NovoCure. MarketBeat recorded 10 mentions for Brainsway and 2 mentions for NovoCure. NovoCure's average media sentiment score of 1.67 beat Brainsway's score of 0.41 indicating that NovoCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainsway	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
NovoCure	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Brainsway beats NovoCure on 11 of the 16 factors compared between the two stocks.

Get Brainsway News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BWAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BWAY vs. The Competition

Export

Metric	Brainsway	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$653.42M	$8.00B	$6.29B	$12.46B
Dividend Yield	N/A	2.50%	2.79%	5.30%
P/E Ratio	65.28	18.40	20.87	25.58
Price / Sales	12.51	7.70	521.63	63.56
Price / Cash	71.50	16.76	42.94	55.34
Price / Book	8.73	3.68	9.86	6.70
Net Income	$7.57M	$223.05M	$3.55B	$333.77M
7 Day Performance	-2.33%	-2.09%	-0.32%	0.45%
1 Month Performance	9.02%	3.45%	1.34%	4.06%
1 Year Performance	217.82%	2.02%	41.03%	36.21%

Brainsway Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BWAY Brainsway	2.1255 of 5 stars	$16.32 +0.1%	$15.00 -8.1%	+232.5%	$653.42M	$52.23M	65.28	120	News Coverage Analyst Downgrade
LMAT LeMaitre Vascular	4.5824 of 5 stars	$111.61 +0.1%	$105.80 -5.2%	+17.9%	$2.55B	$249.60M	44.46	490	Insider Trade
WRBY Warby Parker	2.6147 of 5 stars	$21.90 -0.4%	$28.09 +28.3%	+54.0%	$2.35B	$871.91M	1,100.60	4,036	Earnings Report Analyst Upgrade Options Volume
AXGN AxoGen	3.2924 of 5 stars	$42.91 +0.7%	$46.50 +8.4%	+270.3%	$2.29B	$238.11M	N/A	450
ESTA Establishment Labs	3.5224 of 5 stars	$72.26 +2.9%	$86.86 +20.2%	+97.6%	$2.11B	$211.08M	N/A	1,004	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BWAY) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Brainsway (BWAY) Competitors

BWAY vs. LMAT, WRBY, AXGN, ESTA, and NVCR

How does Brainsway compare to LeMaitre Vascular?

Summary

How does Brainsway compare to Warby Parker?

Summary

How does Brainsway compare to AxoGen?

Summary

How does Brainsway compare to Establishment Labs?

Summary

How does Brainsway compare to NovoCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BWAY vs. The Competition

Brainsway Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Brainsway (BWAY) Competitors

BWAY vs. LMAT, WRBY, AXGN, ESTA, and NVCR

How does Brainsway compare to LeMaitre Vascular?

Which has better earnings and valuation, BWAY or LMAT?

Is BWAY or LMAT more profitable?

Do institutionals & insiders have more ownership in BWAY or LMAT?

Do analysts rate BWAY or LMAT?

Which has more volatility and risk, BWAY or LMAT?

Does the media refer more to BWAY or LMAT?

Summary

How does Brainsway compare to Warby Parker?

Is BWAY or WRBY more profitable?

Do analysts rate BWAY or WRBY?

Do institutionals & insiders have more ownership in BWAY or WRBY?

Which has better earnings and valuation, BWAY or WRBY?

Does the media refer more to BWAY or WRBY?

Which has more volatility and risk, BWAY or WRBY?

Summary

How does Brainsway compare to AxoGen?

Is AXGN or BWAY more profitable?

Do analysts prefer AXGN or BWAY?

Do insiders and institutionals have more ownership in AXGN or BWAY?

Which has stronger valuation and earnings, AXGN or BWAY?

Does the media prefer AXGN or BWAY?

Which has more volatility and risk, AXGN or BWAY?

Summary

How does Brainsway compare to Establishment Labs?

Is ESTA or BWAY more profitable?

Which has higher valuation & earnings, ESTA or BWAY?

Does the media prefer ESTA or BWAY?

Which has more risk and volatility, ESTA or BWAY?

Do analysts prefer ESTA or BWAY?

Do institutionals and insiders have more ownership in ESTA or BWAY?

Summary

How does Brainsway compare to NovoCure?

Do analysts rate BWAY or NVCR?

Do institutionals and insiders have more ownership in BWAY or NVCR?

Is BWAY or NVCR more profitable?

Which has more volatility & risk, BWAY or NVCR?

Which has stronger valuation and earnings, BWAY or NVCR?

Does the media favor BWAY or NVCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BWAY vs. The Competition

Brainsway Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools